Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 3Phase 2/3 2Phase 1/2 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Genitourinary 1

Conditions

Neoplasms 3Pancreatic Neoplasms 1Neoplasm Metastasis 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 524Specimen Handling 383Carboplatin 377Magnetic Resonance Spectroscopy 336Cisplatin 332Nivolumab 308Cyclophosphamide 298Radiotherapy 257Paclitaxel 255Gemcitabine 235Biopsy 235Bevacizumab 218Dexamethasone 169durvalumab 168Oxaliplatin 163Capecitabine 158Rituximab 157Fluorouracil 149venetoclax 147Docetaxel 147Etoposide 142Drug Therapy 142atezolizumab 141Doxorubicin 134Ipilimumab 129Radiosurgery 120Prednisone 120Lenalidomide 119Leucovorin 113fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × budigalimab × 1 year × Clear all
NCT06119217 2026-05-13

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Trishula Therapeutics, Inc.

Phase 2 Completed
194 enrolled 16 charts
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT05822752 2025-08-14

LIVIGNO-1

AbbVie

Phase 2 Active not recruiting
130 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT06632951 2025-08-11

LIVIGNO-3

AbbVie

Phase 2 Active not recruiting
150 enrolled
Genitourinary

Carcinoma, Transitional Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡